MDMA (Ecstasy) use during pregnancy is linked to poorer motor quality and lower milestone attainment in infants at 4 months, with a dose-response relationship: greater exposure corresponds to worse motor outcomes. This first prospective study of prenatal MDMA exposure in humans compared 28 women who used MDMA during pregnancy with 68 polydrug-using women who did not, controlling for confounding factors. MDMA-using mothers had fewer prior births and more health, work, and social problems. Exposed infants were more likely to be male. The findings suggest risk to the developing infant and indicate that continued follow-up is needed to determine whether early motor delays persist or resolve.
Heavier prenatal exposure to MDMA (ecstasy) predicted poorer mental and motor development in 12-month-old infants, with motor delays appearing in a dose-dependent manner. Lighter-exposed infants were comparable to nonexposed infants. No effects were found on language, emotional regulation, or parenting stress. The study involved 96 women in the United Kingdom—28 who used MDMA during pregnancy and 68 who did not—and used standardized developmental assessments.
A longitudinal study tracked infants whose mothers used MDMA (ecstasy) during pregnancy to assess developmental effects. The review of findings suggests that prenatal MDMA exposure may be associated with delays in motor development and increased risk of fine motor deficits during infancy. The authors indicate that the observed effects appear to be dose-dependent, with heavier use linked to more pronounced developmental differences. The findings point to potential neurodevelopmental consequences of prenatal MDMA exposure, though the authors note that confounding factors such as other substance use and socioeconomic conditions complicate interpretation.